
(IN BRIEF) Boehringer Ingelheim and CDR-Life have reported positive results from the Phase I trial of BI 771716, an investigational treatment for geographic atrophy (GA), a severe form of age-related macular degeneration. The antibody fragment met its primary safety endpoints, … Read the full press release